
Metamucil is owned by Procter & Gamble (NYSE: PG), a publicly traded consumer goods corporation headquartered in Cincinnati, Ohio. P&G acquired Metamucil in 1985 through its purchase of Richardson-Vicks. Metamucil is the leading fiber supplement brand in the United States with approximately 30% market share.
Parent Company
Acquired
1985
Status
Publicly Traded
Headquarters
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Metamucil | Procter & Gamble Company | Wholly owned |
Metamucil was introduced in 1934 by G. D. Searle & Company as a bulk-forming fiber laxative made from psyllium husk. The product was developed to provide a natural approach to promoting digestive regularity through dietary fiber supplementation. Psyllium husk, derived from the Plantago ovata plant, has been used in traditional medicine for centuries as a natural laxative.
The brand name combines "meta" (meaning change or beyond) with "mucil" (referring to the mucilage properties of psyllium). In the 1930s and 1940s, the product gained recognition among physicians and pharmacists as an effective treatment for constipation. Distribution was initially limited to pharmacies and medical channels.
In the 1960s and 1970s, Metamucil expanded its product line with flavored powder formulations to improve taste and patient compliance. The brand also began investing in clinical research to demonstrate health benefits of psyllium fiber beyond laxative effects. Studies published in peer-reviewed journals showed that psyllium fiber could help lower cholesterol levels and improve blood sugar management. These findings allowed the brand to expand its health claims over time.
Richardson-Vicks acquired Metamucil from Searle as part of its expansion into health care products. Under Richardson-Vicks, the brand introduced new delivery formats including capsules and wafers, making the product more convenient for consumers who did not want to mix powder into water.
In 1985, Procter & Gamble acquired Richardson-Vicks for approximately $1.2 billion. The deal brought Metamucil, Vicks, and other brands into P&G's portfolio. Under P&G's ownership, Metamucil continued to expand its product range. The brand added sugar-free formulations, gummies, and additional flavors. P&G also leveraged its marketing and distribution infrastructure to expand Metamucil's availability from pharmacies to mass retail channels including grocery stores, big-box retailers, and online marketplaces.
In September 2024, P&G launched Metamucil Fiber Gummies in major retail chains across North America. The gummy format targets consumers who find powder and capsule formats inconvenient or unpalatable. This launch reflected a broader trend in the supplement industry toward gummy delivery formats.
As of 2026, Metamucil remains the number one doctor-recommended fiber brand, based on ProVoice survey data from 2023. The brand's psyllium-based products are the only leading fiber supplement powered by psyllium husk, according to P&G's marketing materials, which differentiate the brand from competitors like Benefiber (wheat dextrin) and Citrucel (methylcellulose).
Procter & Gamble delivered mixed financial results in fiscal 2026, reflecting both the strength of its business model and challenges in the current consumer environment. In Q2 2026, P&G reported adjusted earnings per share of $1.88, exceeding Wall Street expectations of $1.86, while revenue of $22.21 billion fell slightly short of analyst expectations of $22.28 billion. The company's ability to beat earnings estimates despite revenue challenges demonstrates the effectiveness of its productivity initiatives and cost management strategies.
Financial Performance Overview shows P&G's resilience in a challenging market. The company revised its fiscal 2026 earnings outlook to 1% to 6% net earnings per share growth, down from the previous forecast of 3% to 9%, citing higher restructuring charges. Despite this adjustment, P&G maintained its sales growth guidance, reflecting confidence in its business fundamentals and strategic positioning. CFO Andre Schulten noted that "We've now completed what we fully expect will be the softest quarter of the fiscal year," indicating anticipation of improved performance in the second half.
Volume Performance revealed significant challenges across key categories, with overall volume falling 1% as three out of five product categories reported shrinking volume. This decline reflects broader consumer behavior patterns as inflation-weary consumers hunt for deals and reduce discretionary spending, particularly in P&G's largest market, the United States. Despite these challenges, Schulten emphasized that "People have not stopped washing their hair, they still buy diapers, they do their laundry — albeit at a little bit slower pace, so the market growth has certainly slowed over the last 18 to 24 months."
Segment Performance showed divergent trends across P&G's business portfolio. The baby, feminine and family care segment experienced the steepest decline with volume falling 5% in Q2 2026, facing tough comparisons with the year-ago period when retailers and consumers stocked up ahead of expected port strikes. The grooming business, which includes Gillette and Venus razors, reported a 2% volume drop, reflecting ongoing competitive pressures in the men's grooming market. The health-care segment saw volume fall 1%, including brands like Oral-B, Vicks, and Pepto-Bismol.
Bright Spots in Performance were primarily in the beauty segment, which was the only division to report volume growth, rising 3% fueled by stronger demand for hair-care products. The fabric and home-care business, which includes brands like Febreze and Tide, reported unchanged volume, demonstrating stability in P&G's largest business segment by revenue. These performance variations highlight the importance of P&G's diversified portfolio strategy in navigating market challenges.
Q1 2026 Results demonstrated stronger performance compared to Q2, with net sales of $22.4 billion, up 3% versus the prior year, and organic sales increasing 2%. The company achieved diluted EPS of $1.95 (up 21% YoY) and core EPS of $1.99 (up 3% YoY), reflecting strong operational execution. Operating cash flow was $5.4 billion, and the company returned $3.8 billion to shareholders through dividend payments and share repurchases, demonstrating P&G's commitment to shareholder returns.
Consumer Market Dynamics continue to shape P&G's performance, with the company facing "softer consumer markets, aggressive competition, and a dynamic geopolitical landscape" according to CFO Schulten. These challenges reflect broader economic pressures affecting consumer spending patterns and competitive intensity in key categories. However, P&G expects stronger results in the second half of the fiscal year, fueled by upcoming innovation and improved market conditions.
Innovation and Demand Creation remain central to P&G's strategy for driving growth. The company is increasing investment in innovation and demand creation to improve value for consumers and drive category growth. This focus on innovation is particularly important in the beauty segment, where new product development and marketing initiatives have helped drive volume growth despite overall market challenges.
Q3 2026 Results showed a significant acceleration in performance. P&G reported net sales of $21.24 billion, up 7% versus the prior year, beating Wall Street expectations of $20.5 billion. Organic sales increased 3%, driven by a 2% increase in volume — the first time in a year that P&G reported growing volume across the company. Core EPS of $1.59 beat estimates of $1.56, up 3% YoY. Diluted EPS was $1.63, up 6%, boosted by a gain from the dissolution of the Glad joint venture business. CEO Shailesh Jejurikar stated: "We delivered a solid acceleration in top-line results in our fiscal third quarter, with broad-based growth across product categories and regions." All five segments posted net sales growth: Beauty +11% ($3.87B), Fabric & Home Care +7% ($7.4B), Baby/Feminine/Family Care +6% ($5.06B), Health Care +7% ($3.07B), and Grooming +7% ($1.61B). The company returned $3.2 billion to shareholders via $2.5 billion in dividends and over $600 million in share repurchases. However, P&G warned about uncertainty from the Iran war's effects on input costs and consumer spending, projecting approximately $400 million in after-tax tariff costs and $150 million in commodity cost headwinds. If Brent crude stays around $100/barrel, P&G projects an annual after-tax headwind of $1 billion. The company will not provide a fiscal 2027 forecast until its July earnings report.
Leadership Transition Impact represents a significant element of P&G's current strategy. Shailesh Jejurikar's appointment as CEO effective January 1, 2026, brings fresh perspectives while maintaining continuity through Jon Moeller's transition to Executive Chairman. Jejurikar described his vision at the CAGNY Conference: leveraging P&G's strengths to "create the CPG company of the future."
Geographic Performance varied across P&G's global markets, with the United States facing particular challenges due to consumer behavior changes and competitive pressures. However, the company's global diversification provides stability, with different regions experiencing varying levels of economic pressure and consumer demand patterns.
Supply Chain and Operations have been optimized to support P&G's productivity initiatives and cost management strategies. The company's integrated supply chain encompasses suppliers, manufacturing partners, and retailers in complex networks ensuring product availability worldwide while maintaining operational efficiency.
Future Outlook remains cautiously optimistic, with P&G maintaining its fiscal year 2026 guidance for all-in sales growth of 1% to 5% and net EPS growth of 1% to 6% versus FY2025 diluted EPS of $6.51. Core EPS growth guidance is in-line to up 4% versus FY2025 core EPS of $6.83, equating to $6.83 to $7.09 per share. However, earnings are expected to trend toward the lower end of the range as cost headwinds persist and investments step up. The company faces approximately $400 million in after-tax tariff costs and $150 million in commodity cost headwinds. P&G will not provide a fiscal 2027 forecast until its July 2026 earnings report, citing uncertainty from the Iran war's impact on input costs and consumer spending.
Investor Confidence remained strong despite mixed results, with P&G shares rising more than 2% in morning trading following the Q2 earnings announcement. This positive market response reflects investor confidence in P&G's ability to navigate current challenges while positioning for future growth through strategic initiatives and operational excellence.
P&G's recent performance demonstrates the company's ability to maintain profitability and shareholder returns while navigating challenging market conditions. The combination of operational efficiency, brand strength, and strategic focus on innovation provides a solid foundation for continued success in the competitive consumer goods industry.
Metamucil's sustainability practices are governed by Procter & Gamble's corporate environmental framework. P&G has set goals including 100% of packaging being reusable, recyclable, or compostable, and net zero greenhouse gas emissions across operations and supply chains by 2040. However, these are corporate-level commitments, and Metamucil-specific sustainability metrics are not independently reported.
The brand does not hold independent certifications such as B Corp, organic certification, or fair trade certification. These certifications are not standard in the dietary supplement category. P&G's supplier code of conduct applies to Metamucil suppliers, covering labor practices and environmental compliance.
The primary ingredient, psyllium husk, is sourced from India. P&G's responsible sourcing program includes commitments to sustainable agriculture and supply chain transparency. However, specific details about psyllium farming practices, farmer welfare programs, or environmental impact assessments for Metamucil's supply chain are not publicly available.
Packaging for Metamucil powder containers uses recyclable materials. P&G has reported progress on reducing packaging weight across its portfolio, though brand-specific data for Metamucil is not disclosed.
Metamucil's recognition comes primarily from market position rather than formal industry awards. The brand has been ranked as the number one doctor-recommended fiber brand based on ProVoice survey data from 2023, a recognition that P&G uses prominently in its marketing.
NielsenIQ data has consistently cited Metamucil as the top-selling psyllium fiber supplement in the United States. The brand's 30.2% market share in the fiber supplement category reflects sustained consumer trust and retail performance over its 90-plus year history.
Metamucil does not typically receive product design or innovation awards, as it operates in the functional health category rather than consumer lifestyle segments. Within P&G's portfolio, the brand is recognized as a consistent performer in the Health Care segment, though P&G does not break out individual brand revenue figures publicly.
In February 2024, P&G recalled 257,136 bottles of Metamucil Psyllium Fiber Capsules distributed across 41 states. The recall affected 21,428 cases of the product due to potential microbial contamination concerns. The FDA issued warnings about the affected products, which were removed from retail shelves. P&G cooperated with regulatory authorities and implemented enhanced quality control measures. The recall was classified as Class III, indicating a low probability of adverse health consequences but a situation where exposure could cause temporary or medically reversible adverse effects.
In December 2023, a class-action lawsuit was filed against Procter & Gamble alleging that certain Metamucil products contained dangerous levels of lead. The lawsuit claimed that P&G failed to adequately disclose the presence of lead in its psyllium fiber products. Independent testing by ConsumerLab.com in 2024 found elevated lead levels in some psyllium supplements, raising concerns about heavy metal contamination in the category. The lawsuit remains ongoing as of 2026, with P&G maintaining that its products meet safety standards.
Metamucil products carry FDA-mandated warnings about potential allergic reactions in people sensitive to inhaled or ingested psyllium. Documented cases of occupational asthma and allergic reactions exist among healthcare workers and individuals with repeated psyllium exposure. These warnings are standard for psyllium-based products and are not specific to Metamucil.
The FDA has periodically reviewed Metamucil's marketing claims to ensure compliance with dietary supplement regulations. Health claims related to heart health and cholesterol reduction require FDA authorization. P&G has worked to maintain compliance with evolving regulatory requirements while communicating the scientifically supported benefits of psyllium fiber supplementation.
No direct competitors found in the same category. This could be because Metamuciloperates in a unique market segment or we're still building our competitor database.
Looking for brands with different ownership structures? These similar brands are not owned by Procter & Gamble Company, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by Chempro Chemists
Australian online pharmacy operated by Chempro Chemists from Molendinar, Queensland. Offers prescription medications, health products, and wellness items through digital platforms and mail-order delivery.
Pharmacy Direct is privately owned, unlike Metamucil which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
Tirosint is privately owned, unlike Metamucil which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Bausch + Lomb Corporation
Global eye health company and contact lens manufacturer founded in 1853, known for ULTRA, Biotrue One Day, and INFUSE lens lines. Public on NYSE and TSX under BLCO.
Bausch + Lomb operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by GoodRx Holdings, Inc.
American healthcare technology platform providing prescription drug price comparison, discount coupons, and telehealth services to help consumers find affordable healthcare options.
GoodRx operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Herbalife Ltd.
Global nutrition and weight-management brand owned by Herbalife Ltd. and sold through independent distributors in more than 90 markets.
Herbalife operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by EKR Therapeutics, Inc.
Retavase (reteplase) is a prescription thrombolytic medication indicated for acute ST-elevation myocardial infarction. Administered as two 10-unit intravenous bolus injections 30 minutes apart. Currently marketed by Chiesi USA.
Retavase is privately owned, unlike Metamucil which is under a publicly traded parent company.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.

Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.